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ABSTRACT
Coronavirus disease 19 (COVID-19) is caused by SARS-Cov-2 and the manifestations 
of this infection range from an absence of symptoms all the way up to severe disease 
leading to death. To estimate the prevalence of past infection in a population, the most 
readily available method is the detection of antibodies against the virus. This study has 
investigated the prevalence of anti-SARS-CoV-2 antibodies in outpatients of the Hospital 
das Clinicas, in Sao Paulo city (Brazil), which is a large university hospital belonging to 
the public health system that cares for patients with complex diseases who need tertiary or 
quaternary medical care. Our serological inquiry was carried out for 6 weeks, with once-a-
week blood sampling and included 439 patients from several outpatient services. Overall, 
61 patients tested positive for anti-SARS-CoV-2 IgG (13.9%); 56.1 % of the patients live in 
Sao Paulo city, with the remaining living in other towns of the metropolitan area; 32.8% of 
the patients testing positive for IgG antibodies to SARS-CoV-2 were asymptomatic, 55.7% 
developed mild or moderate disease and 11.5% had to be hospitalized. The prevalence of 
SARS-CoV-2 positive serology was lower among patients who had received the seasonal 
influenza vaccine compared to the ones who did not. These findings may indicate that those 
individuals care more about health issues, and/or that they have a better access to health 
care and/or a better quality of health care service. The large proportion of patients who 
were unaware of having had contact with SARS-CoV-2 deserves attention, reflecting the 
scarcity of tests performed in the population.
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INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative 
agent of the ongoing outbreak of coronavirus disease 2019 (COVID-19), that started 
in Wuhan, China at the end of 2019, and had already killed about 917,000 people 
worldwide1. SARS-CoV-2 are enveloped non-segmented positive-sense RNA viruses 
belonging to the Coronaviridae family2,3. Clinical manifestations include a variety 
of respiratorysymptoms, varying from mild to severe, which are associated with 
high mortality4,5.
In Brazil, up to September 12th 2020, more than 4 million cases had been 
registered, including more than 130 thousand deaths6. The community transmission 
of SARS-CoV-2 is widespread in Brazil, with the city of Sao Paulo as the first 
epicenter of the disease. The city is surrounded by several neighboring towns, 
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making up the Metropolitan Area of Sao Paulo, with a 
population estimated at 21.5 million people, where about 
500 thousand COVID-19 cases, including 22 thousand 
deaths, had been registered up to September 20207. In the 
last household inquiry to monitor the seroprevalence of 
infection by SARS-CoV-2 virus in adults in the city of Sao 
Paulo, a seroprevalence of 17.9% was estimated, meaning 
that more than 1.5 million people had already antibodies 
to SARS-CoV-2 in the city at that time8.
Serological tests to detect IgG antibodies against 
SARS-CoV-2 play an important role in estimating the true 
prevalence of the virus in the population, and to identify 
individuals who are potentially immune to reinfection9, 
especially in countries where testing is scarce, as in Brazil. 
Furthermore, these are extremely relevant data for planning 
the resumption of activities in the city.
Additionally, there is also a portion of the population 
that remains asymptomatic or has only subclinical infection, 
representing a blind spot for intervention measures to 
control contagion and track individuals who have already 
had contact with the virus. Studies have found proportions 
of asymptomatic people ranging from 4-80% across 
different populations and exposure rates10.
The Hospital das Clinicas of the University of Sao 
Paulo Medical School is the largest hospital complex in 
Brazil, receiving thousands of patients every day, both 
from the city of Sao Paulo and from surrounding areas. We 
investigated the prevalence of antibodies to SARS-CoV-2 
among patients who came for routine tests blood sampling. 
Data on the patients’ age, gender, place of residence and 
influenza vaccination status were also obtained.
MATERIALS AND METHODS
Patient population and samples collection
We collected blood samples from 439 adult patients 
followed-up at various outpatient services of the hospital. 
Patients came to the clinical laboratory to collect samples for 
routine tests requested by their physicians. We obtained an 
informed and signed consent to perform the SARS-CoV-2 
serological test, in addition to their other exams. Samples 
were collected on a weekly basis for six consecutive weeks, 
from June 30th to August 4th, 2020.
The sample size was calculated based on previous 
results obtained by the hospital clinical pathology 
laboratory during the validation of the serological 
tests. The 5% prevalence found in the validation led 
us to assume a 6% prevalence in our study, with a 95% 
confidence interval ranging from 3-8% in a study with test 
power of 80%. As the daily number of patients coming 
to the laboratory for routine blood drawing was around 
300 at that time, and we planned a once-a-week blood 
samplings, we estimated the sample size at 346, based 
on the assumptions described above (approximately 70 
samples per week, during five consecutive weeks, instead 
of the six weeks previously planned). Later on, a sixth 
week was included in the study, resulting in a total of 
439 enrolled patients. Blood sampling was carried out 
always on the same day of the week (on Tuesdays) and 
the research team was specifically trained to employ a 
convenient approach to invite the patients to participate 
in the study. We obtained written informed consent from 
all pateints, according to the protocol of the Hospital das 
Clinicas Ethical Committee, following the guidelines of 
resolution 466/2012 from the National Commission for 
Ethics in Research with human beings. 
Serological tests
Five milliliters of venous blood were drawn from the 
patients’ arms. Then, samples were centrifuged to obtain 
serum samples that were analyzed by an automated 
quantitative chemiluminescence assay to determine 
IgG antibodies titers raised to proteins S1 and S2 of 
SARS-CoV-2 by using LIAISON® SARS-CoV-2 S1/S2 
IgG (DiaSorin S.p.A., Saluggia, Italy). This assay was 
validated by testing 162 samples, reaching a sensitivity of 
97.8% and specificity of 99.1% 14 days after symptoms 
onset. Samples with inconclusive results and antibody 
titles between 12 and 15 UA/mL were retested by another 
electrochemiluminescence immunoassay for the detection 
of total Ig antibodies (IgM and IgG) directed to the NC 
protein of SARS-CoV-2, using the Elecsys Anti-SARS-
CoV-2 Cobas® assay (Roche Diagnostics GmbH, 
Mannheim, Germany). For this assay, the sensitivity was 
90% and specificity about 100% 14 days after symptoms 
onset.
Statistical analysis
We performed the statistical analysis and graphical 
representation using the GraphPad Prism (version 8.0.1, 
GraphPad Software, La Jolla, CA, USA). We used the 
Student’s t test, one-way analysis of variance (ANOVA) 
and nonparametric Kruskal-Wallis tests for comparison of 
means and the chi-square test for comparing proportions. 
The statistical significance was set at p<0.05. We used 
coordinated geographic data for data mapping, with the aid 
of the geographic mapping software QGIS (version 3.14.1, 
Free Software Foundation, Inc., Boston, MA, USA).
Rev Inst Med Trop São Paulo. 2020;62:e91
Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil
Page 3 of 8
RESULTS
Samples collection and gender characteristics of the 
patients
We included 439 outpatients who came for routine 
laboratory tests, from June 30th to August 4th, 2020, and 
blood sampling was performed once a week for six 
consecutive weeks. Serum samples were tested for the 
presence of anti-SARS-CoV-2 IgG antibodies. Samples with 
inconclusive results from five patients (1.1%) were retested 
with a different serological kit, this time for detecting total 
antibody titles raised to SARS-CoV-2. Four of them proved 
to be non-reactive and one turned out to be reactive. For 
convenience, henceforth, we refer to all positive samples 
as anti-SARS-CoV-2 positive IgG. We found aweekly 
increase of seroprevalence in the first 3 weeks, an upward 
trend that did not last for the next three weeks (Figure 1). 
Overall, 61 patients (13.9%) tested positive for antibodies 
anti-SARS-CoV-2; 64.5% of our sample was composed of 
female patients, but this gender proportion was lower among 
those testing positive to anti-SARS-CoV-2 IgG antibodies 
that was 57.4 % (Table 1).
Distribution of cases by age group
All adulthood age groups were represented in our sample, 
with the following distribution: 27.6% in the age group 18-39 
years old; 42.1% in the group 40-59 years and 30.3% in those 
≥ 60 years old. The age group profile of positive anti-SARS-
CoV-2 IgG patients, in turn, was slightly higher in the group 
18-39 years (31.2%), and 54.1% in the 40-59 group. Patients 
aged 60 years and over represented only 14.8% of the anti-
SARS-CoV-2 positive IgG patients, showing a decrease of 
50% in the proportional participation of this age group as 
compared with that of the whole sample (Figure 2). 
Patients’ residence profile
The Hospital das Clinicas complex is a tertiary/
quaternary medical facility that serves patients in the public 
health system. All medical specialties and subspecialties 
are present in the complex. Its patients come from all areas 
of the city of Sao Paulo (divided into sectors), and from 
its five surrounding subregions that together make up the 
Metropolitan Area of Sao Paulo.
According to Figure 3, among the 439 investigated 
patients, 56.1% reside in the city of Sao Paulo, while 
43.9% live in one of its subregions (Figures 3A and 3B). 
Considering only the patients who live in the city of Sao 
Paulo, 32/252 or 12.7% presented with positive tests to anti-
SARS-CoV-2 IgG antibodies, while among the 152 patients 



















Figure 1 - Weekly seropositivity for SARS-CoV-2. Percentage 
of positive patients for IgG anti-SARS-CoV-2, according to each 
week of the survey. 
Figure 2 - Distribution of patients according to age groups 
(years). Patients were analyzed according to the different age 
groups. On the left is the total number of studied patients; on 
the right, are the postive patients for IgG anti-SARS-CoV-2.
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Figure 3 - Mapping of the origin of patients living in the Metropolitan Area of Sao Paulo. (A) The Metropolitan Area was divided 
into the city of Sao Paulo and subregions. Negative and positive patients for IgG anti-SARS-CoV-2 were represented by dots. (B, 
C and D). The percentage of positive patients for IgG anti-SARS-CoV-2 in the city of Sao Paulo and subregions (B); subregions of 
the Metropolitan Area of Sao Paulo (C); and sectors of the city of Sao Paulo (D).
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who live in the subregions, 29/152 or 19.1% presented with 
anti-SARS-CoV-2 IgG antibodies.
Concerning the patients who live in the city of Sao Paulo 
(Figure 3C), specific anti-SARS-CoV-2 IgG was found in 
individuals from all five regions, 34.4% coming from the 
South sector, 31.2% from the East and 21.9% from the 
Western sector, whereas the North contributed with 9.4% 
and the Central sector with 3.1%. 
Patients living in the metropolitan area outside the city 
of Sao Paulo who had positive anti-SARS-CoV-2 antibodies 
came most from the Eastern subregion (40%), followed by 
36% from the Western subregion, whereas 20% and 4% of 
them live in the Southwestern and Southeastern subregions, 
respectively. None of the patients from the Northern 
subregion had antibodies anti-SARS-CoV-2 (Figure 3D).
Patients IgG anti-SARS-CoV-2 antibody titers
Sixty-one patients (13.9%), from the total sample of 
439 individuals, had positive IgG anti-SARS-CoV-2, and 
only 2% (9/439) had a previous diagnosis of COVID-19 
(Figure 4, black symbols). Among those presenting with 
antibodies anti-SARS-CoV-2, 32.8% (20/61) did not report 
symptoms, 55.7% (34/61) had symptoms of COVID-19 and 
11.5% (7/61) were admitted to hospitals. Non-hospitalized 
patients experienced a variety of symptoms of COVID-19, 
such as fever or chills, cough, shortness of breathe or 
respiratory distress, fatigue, muscle or body aches, 
headache, loss of taste or smell, sore throat, congestion 
or runny nose, nausea and diarrhea. Hospitalized people 
related cough, shortness of breath or difficulty breathing, 
fatigue, muscle or body aches, loss of taste or smell, sore 
throat, stuffy or runny nose and diarrhea. None of them 
needed respiratory y support. According to Figure 4 IgG 
titers among hospitalized patients were significantly higher 
than those of non-hospitalized ones (p=0.02).
Patients profile according to influenza vaccination 
status
We have also investigated whether influenza vaccination 
status was associated with the serological status for 
SARS-CoV-2. We did not retrieve information on the 
vaccination status of four patients, so that, for this analysis, 
we included a total of 435 patients. We observed that 69% 
(300/435) of the patients were vaccinated, while 31% 
(135/435) were not immunized against influenza. Among 
the vaccinated patients, 11.3% (34/300) were positive 
for anti-SARS-CoV-2 IgG antibodies, whereas among 
non-vaccinated patients 20% (27/135) were positive 
(p=0.016) (Table 2).
DISCUSSION
Knowledge on the prevalence of COVID-19 in a 
population is essential for the adoption of public health 
actions and reopening decisions, constituting a great 
challenge in regions where diagnostic tests are scarce, such 
as in Brazil.
Considering the different symptoms severity scales 
among infected individuals, ranging from absence of 
symptoms all the way up to severe manifestations that can 
lead to death, it is not surprising that a considerable part 
of the population does not know whether or not they have 
had contact with the virus. In this context, we proposed 
to determine the anti-SARS-CoV-2 serological profile 
of outpatients of the Hospital das Clinicas, a tertiary/
quaternary hospital that serves the population of the 
Figure 4 - IgG anti-SARS-CoV-2 titers. Patients were divided 
according to the presence of symptoms into asymptomatic 
(n: 20) and symptomatic (non-hospitalized n: 34) and 
hospitalized (n: 7) patients who have already had a previous 
diagnosis for COVID-19 are shown in black. One-way ANOVA 
and the non-parametric Kruskal-Wallis test were used for the 
comparison of groups. *p=0.02






Anti-Influenza vaccinated 34 (11.3) 266 (88.7) 300
Anti-Influenza non-vaccinated 27 (20.0) 108 (80.0) 135
Total 61 (14.0) 374 (86.0) 435
Qui-square test=5.8; p=0.016; Odds ratio=0.5121; 95% CI=0.2944 to 0.8737
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Metropolitan Area of Sao Paulo, a location that was the first 
and the most affected by COVID-19 in Brazil.
We found a prevalence of 16.6%of positive serology 
to SARS-CoV-2 in men and 12.4 % in women, results 
that are similar to those found in a study developed in the 
Northeastern Ceara State (Brazil), that has a also found 
higher prevalence in men in comparison with women11. 
During the first three weeks of our study, we found weekly 
increases on the frequency of positive anti-SARS-CoV-2 IgG 
antibodies, followed by a decrease and subsequent increment 
in these frequencies in the last week. In the phase zero of 
a serological survey in the city of Sao Paulo, samples were 
collected in the second half of June, and the mean prevalence 
of antibodies anti-SARS-CoV-2 in the population of the city 
was 9.5%12. At the same time, during the first week of blood 
sampling in the present study, only 5.5% of our patients were 
positive, the frequency incresed to 15.5% in the second week 
and to 20.8% in the third week. Close to this date, results of 
phase 2 of the serological survey in the city were released, 
showing a prevalence of 11.1%12. In general, our survey in 
outpatients of the Hospital das Clinicas found a prevalence 
of 13.9%, while the estimate for the city of Sao Paulo was 
10.9% on the same time point of the last week of our study. 
It is worth noting that our patients were distributed in all 
groups of adulthood and they came from different regions 
of the city of Sao Paulo as well as from several neighboring 
towns surrounding the city.
We found that patients aged 60 years old and over 
corresponded to 30% of the sample, but only about 15% 
of them had positive SARS-CoV-2 serology. Considering 
that patients in that age group are at higher risk for a more 
severe course of COVID-19, we hypothesize that they were 
more adherent to the measures to minimize the risk of 
contagion, such as social distance , use of masks and more 
rigid hand hygiene. 
Focusing on the city of Sao Paulo, we found that the 
Eastside sector had the highest proportion of positive 
patients, with 34.4%, followed by the South sector with 
31.2% and the Westside one with 21.9%. The Northern 
and Central sectors had lower prevalences, of only 9.4% 
and 3.1%. Results of the phase 3 of a serological survey in 
the city of Sao Paulo12 showed that, like our findings, the 
South and East sectors seem to be the most affected ones. 
It is important to note that in that survey, the distribution 
of residences was representative of all areas of the city, 
whereas in our hospital-based survey, the distribution was 
not fully representative of the whole population of the city.
Another serial seroepidemiological survey on the 
prevalence of SARS-CoV-2 infection (SoroEpi MSP)8 in the 
city of Sao Paulo included 1,470 blood samples collected 
from July 20th to 29th, and showed that 17.9% of the adult 
population had already been infected by SARS-CoV-2. 
Although laboratory test and commercial kits were different 
between studies and the fact that our data are restricted to 
samples from the Hospital das Clinicas outpatients, our 
13.9%prevalence of seropositivity was not very far from 
the findings of that study.
We have also investigated a possible association between 
antibody IgG titers raised to SARS-CoV-2 and the severity 
of COVID-19 infection. According to our data, IgG titers 
were higher in hospitalized compared to non-hospitalized 
patients. Corroborating our findings, several studies have 
associated higher levels of anti-SARS-CoV-2 antibodies 
with severity of COVID-1913,14.
Previous reports have indicated that a substantial fraction 
of SARS-CoV-2-infected individuals are asymptomatic or 
present with only mild symptoms15-17. Data obtained in the 
present study showed that most studied patients (55.7%) 
had mild or moderate symptoms of COVID-19. In general, 
considering that only 2% of our sample had a previous 
diagnosis of COVID-19 and that almost half of those who 
presented with positive IgG antibodies anti-SARS-CoV-2 
live in neighboring cities, our findings reinforce the notion 
that the spread of SARS-CoV-2 could be favored by 
undiagnosed infections.
We have also investigated the seasonal influenza 
immunization status among our patients. The prevalence 
of positive serology for SARS-CoV-2 was lower among 
those who took the vaccine compared to the ones who did 
not. This finding may indicate that there is a more careful 
health behavior among vaccinated patients, who cared 
enough to take the influenza vaccine and they probably 
pay more attention and avoid practices with a higher risk 
of SARS-CoV-2 transmission, consequently lowering 
the proportion of infection and of positive serology to 
SARS-CoV-2 in this group. 
Serological surveys are very useful tools to estimate the 
proportion of people who may be, at least in part, protected 
against SARS-CoV-2. It also enables the knowledge on the 
profile of the most vulnerable individuals, in order to guide 
public policies aimed at fighting the infection. In our study, 
we focused on a differentiated population sample, composed 
of outpatients periodically monitored by the medical team. 
We observed that the profile of patients of Hospital das 
Clinicas that have already had contact with the virus is 
similar to that of the general population of the city of Sao 
Paulo in terms of the prevalence of seropositivity, gender 
and place of residence.
We have found a reasonable coverage of influenza 
immunization and a lower seropositivity among immunized 
patients as compared to those not vaccinated and also a 
lower prevalence of anti-SARS-CoV-2 antibodies in the 
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elderly. Both findings indicate that vaccinated individuals 
care more about health issues, and/or that they have better 
access and better quality of health care. The large proportion 
of patients who were unaware of having had contact with the 
virus is due to the well-known fact that many infected people 
are asymptomatic and are not tested, with the consequent 
potential of a further spreading of the virus.
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